Work

A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2537

Authors: Florence Atrafi, Oliver Boix, Prabhu Rajagopalan, Anthony W. Tolcher, Patricia LoRusso, Joseph Paul Eder, Kamalesh Kumar Sankhala, Sant P. Chawla, Vivek Subbiah, Jennifer Robinson Diamond, Martin Gutierrez, Ron H.J. Mathijssen, Jian Mei, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema

Institutions: Erasmus MC Cancer Institute, Bayer (Germany), Bayer (United States), South Texas Accelerated Research Therapeutics, Yale Cancer Center, Yale University, Cedars-Sinai Medical Center, Sarcoma Oncology Center, The University of Texas MD Anderson Cancer Center, Hackensack University Medical Center, Erasmus MC

Language: English

Topic: Statistical Methods in Clinical Trials

Subfield: Statistics and Probability

Field: Mathematics

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891984728

Cites:

Cited by:

Related to: 10